Skip to main content
Shahram  Kordasti

Dr Shahram Kordasti

Reader and Group Leader in Applied Cancer Immunopathology

Research interests

  • Cancer
  • Immunology

Biography

Following his graduation from medical school and clinical training in Internal Medicine/Haematology, Dr Kordasti received his MSc in Medical Immunology and PhD in Cancer Immunology from King's College London. He established the role of regulatory T cells (Tregs) in Myelodysplastic Syndrome (MDS) and their effects on disease progression and response to treatment. In 2018, he was appointed as a senior lecturer at King's College London and continued his work, developing an interest in the immunobiology of aplastic anaemia (AA) during this period. He became a reader (Associate Professor) in Applied Cancer Immunopathology in 2022.

He is also an honorary clinical haematologist at Guy’s Hospital, and he has an interest in MDS, AA, and myeloproliferative neoplasms (MPN). His main research interest lies in the plasticity of CD4+ T cells, their interaction with the inflammatory microenvironment, and their role in the immunobiology of myeloid malignancies. Another focus of his research group is computational biology, multidimensional cytometry, and integrating multiomics data for patient stratification. Additionally, he leads an international consortium, i4MDS, focusing on standardising immune monitoring in patients with MDS.

The publication feed is not currently available.

Research

systems cancer immunology-banner
Systems Cancer Immunology

The main focus of the Systems Cancer Immunology (SCI) group is the role of immune system in the development of Myeloid Malignancies.

Immunology and Immunotherapy Programme Header
Cancer Immunology & Immunotherapy

Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.

Project status: Ongoing

News

King's leads first guideline on immune monitoring in patients with a type of blood cancer

King’s has led on the publication of first-in-their-kind guidelines that seek to standardise how clinicians measure the immune response of patients who have...

A patient lies in a hospital bed, their head is out of frame

King's leads transatlantic consortium to advance immune-monitoring of blood cancer

King’s will lead institutions across Europe and the US in a new consortium to standardise and improve how we monitor the blood cancer Myelodysplastic Neoplasms.

Myelodysplastic Neoplasms consortium

New open-source easy-to-use resource for the analysis of high-dimensional cytometry data launches

ImmunoCluster provides a computational framework for the non-specialist to profile complex high-dimensional data such as mass and flow cytometry.

cell floating

Trial to repurpose cancer drug for patients with COVID-19 launches

A new trial repurposing a blood cancer drug for patients with COVID-19 is being launched.

covid cancer drug

Features

5 minutes with Shahram Kordasti

Shahram Kordasti is a Senior Lecturer and Group Leader in Applied Cancer Immunopathology within the School of Cancer & Pharmaceutical Sciences, and an...

5 minutes with Shahram Kordasti

The publication feed is not currently available.

Research

systems cancer immunology-banner
Systems Cancer Immunology

The main focus of the Systems Cancer Immunology (SCI) group is the role of immune system in the development of Myeloid Malignancies.

Immunology and Immunotherapy Programme Header
Cancer Immunology & Immunotherapy

Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.

Project status: Ongoing

News

King's leads first guideline on immune monitoring in patients with a type of blood cancer

King’s has led on the publication of first-in-their-kind guidelines that seek to standardise how clinicians measure the immune response of patients who have...

A patient lies in a hospital bed, their head is out of frame

King's leads transatlantic consortium to advance immune-monitoring of blood cancer

King’s will lead institutions across Europe and the US in a new consortium to standardise and improve how we monitor the blood cancer Myelodysplastic Neoplasms.

Myelodysplastic Neoplasms consortium

New open-source easy-to-use resource for the analysis of high-dimensional cytometry data launches

ImmunoCluster provides a computational framework for the non-specialist to profile complex high-dimensional data such as mass and flow cytometry.

cell floating

Trial to repurpose cancer drug for patients with COVID-19 launches

A new trial repurposing a blood cancer drug for patients with COVID-19 is being launched.

covid cancer drug

Features

5 minutes with Shahram Kordasti

Shahram Kordasti is a Senior Lecturer and Group Leader in Applied Cancer Immunopathology within the School of Cancer & Pharmaceutical Sciences, and an...

5 minutes with Shahram Kordasti